Redeye updates on Genovis following a new announcement. The company has signed a licensing agreement for its EndoS2 enzyme technology, with potential milestone payments of up to USD20m per project. The deal further strengthens the long-term story and highlights the embedded optionality in the business model.
LÄS MER
